STAT+: Kelonia Therapeutics’ road from floundering to $3 billion

BioAge bets on inflammation, a short Pfizer career, and more biotech news from The Readout
Source
Stat News
Opens original article in a new tab
AI Bias Analysis
4 models · Takes ~15 seconds

BioAge bets on inflammation, a short Pfizer career, and more biotech news from The Readout
Source
Stat News
Opens original article in a new tab

Defense Secretary Pete Hegseth announced Tuesday that the U.S. military will no longer require all American troops to get the flu vaccine.

UnitedHealth’s financial performance in the first quarter far exceeded analyst’s expectations in both its Optum and UnitedHealthcare divisions.

(MedPage Today) -- Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the phase III X-TOLE2 trial showed. Over 12 weeks, adjunctive treatment with 25 mg azetukalner...

We'll be zeroed in on Kennedy's exchanges with one doc in particular: Bill Cassidy.